Glaukos (GKOS) Cash from Financing Activities (2014 - 2026)
Glaukos (GKOS) posted quarterly Cash from Financing Activities of $991000.0 for Q2 2026, down 55.86% year-over-year from $2.2 million in Q2 2025, and down 93.72% quarter-over-quarter from $15.8 million in Q1 2026.
Glaukos (GKOS) Cash from Financing Activities (2014 - 2026) Analysis & Trends
Glaukos (GKOS) has reported Cash from Financing Activities for 13 consecutive years, with $991000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash from Financing Activities fell 55.86% year-over-year to $991000.0; the TTM figure through Jun 2026 stood at $24.5 million (down 66.95% YoY), while the FY2025 annual figure was $11.9 million, down 87.02% from the prior year.
- Cash from Financing Activities declined to $991000.0 in Q2 2026 per GKOS's latest filing, from $15.8 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $60.1 million in Q4 2024 and bottomed at -$880000.0 in Q2 2023.
- Historically, Cash from Financing Activities has averaged $7.9 million across 5 years, with a median of $3.3 million in 2022.
- On a YoY basis, Cash from Financing Activities climbed as much as 1280.53% in 2023 and fell as far as 930.19% in 2023.
- Glaukos' Cash from Financing Activities stood at $529000.0 in 2022, then jumped by 1280.53% to $7.3 million in 2023, then jumped by 723.13% to $60.1 million in 2024, then slumped by 95.96% to $2.4 million in 2025, then plunged by 59.17% to $991000.0 in 2026.
- Business Quant data shows GKOS's Cash from Financing Activities at $991000.0 in Q2 2026, $15.8 million in Q1 2026, and $2.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.44 Bn | 193.84 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Stryker | 127.32 Bn | 123.85 Bn | 4.50 Bn | -95.00 Mn |
| 3 | Medtronic | 118.87 Bn | 109.65 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 73.47 Bn | 72.93 Bn | 3.85 Bn | -410.00 Mn |
| 5 | Edwards Lifesciences | 51.90 Bn | 47.65 Bn | 1.35 Bn | -300,000.00 |
| 6 | Dexcom | 34.30 Bn | 32.36 Bn | 830.00 Mn | -607.30 Mn |
| 7 | GE HealthCare Technologies | 33.74 Bn | 31.63 Bn | 2.18 Bn | -236.00 Mn |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | -1.34 Bn |
| 9 | Steris | 23.05 Bn | 22.56 Bn | 684.20 Mn | -213.50 Mn |
| 10 | Glaukos | 10.81 Bn | 10.70 Bn | 151.59 Mn | 991,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 991,000.00 |
| Jun 30, 2026 | 991,000.00 |
| Mar 31, 2026 | 15.77 Mn |
| Mar 31, 2026 | 15.77 Mn |
| Dec 31, 2025 | 2.43 Mn |
| Dec 31, 2025 | 2.43 Mn |
| Sep 30, 2025 | 5.26 Mn |
| Sep 30, 2025 | 5.26 Mn |
| Jun 30, 2025 | 2.25 Mn |
| Jun 30, 2025 | 2.25 Mn |
| Mar 31, 2025 | 1.95 Mn |
| Mar 31, 2025 | 1.95 Mn |
| Dec 31, 2024 | 60.11 Mn |
| Dec 31, 2024 | 60.11 Mn |
| Sep 30, 2024 | 9.67 Mn |
| Sep 30, 2024 | 9.67 Mn |
| Jun 30, 2024 | 8.59 Mn |
| Jun 30, 2024 | 8.59 Mn |
| Mar 31, 2024 | 13.17 Mn |
| Mar 31, 2024 | 13.17 Mn |